Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NL-OMON50464Phase 1Active, not recruiting
Phase 1, open-label trial of avapritinib in gastrointestinal stromal tumor (GIST) and Nonhematologic neoplasms (3 arms), sponsored by Blueprint Medicines. Primary endpoints: Maximum tolerated dose and recommended phase 2 dose, Safety and tolerability and 1 more. Started Jan 2016; status: active, not recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NL-OMON50464.